Manuela Mollejo

List of Publications by Year
in descending order

109 papers	6,426 citations	46918 47 h-index	69108 77 g-index
110 all docs	110 docs citations	110 times ranked	8214 citing authors

#	Article	IF	Citations
1	Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. Journal of Allergy and Clinical Immunology, 2010, 125, 1269-1278.e2.	1.5	263
2	Primary Cutaneous CD4+ Small/Medium-sized Pleomorphic T-cell Lymphoma Expresses Follicular T-cell Markers. American Journal of Surgical Pathology, 2009, 33, 81-90.	2.1	226
3	Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood, 2003, 101, 681-689.	0.6	224
4	Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood, 2002, 100, 1648-1654.	0.6	184
5	Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood, 2010, 116, 1479-1488.	0.6	174
6	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood, 2011, 117, 1595-1604.	0.6	173
7	EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Modern Pathology, 2012, 25, 968-982.	2.9	172
8	Analysis of the IgVH somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood, 2002, 99, 1299-1304.	0.6	158
9	7q31-32 Allelic Loss Is a Frequent Finding in Splenic Marginal Zone Lymphoma. American Journal of Pathology, 1999, 154, 1583-1589.	1.9	154
10	Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood, 2005, 106, 1831-1838.	0.6	138
11	The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Research, 2003, 63, 8226-32.	0.4	130
12	Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica, 2010, 95, 1342-1349.	1.7	128
13	Progression to Large B-Cell Lymphoma in Splenic Marginal Zone Lymphoma. American Journal of Surgical Pathology, 2001, 25, 1268-1276.	2.1	126
14	Expression of the NF-Î¹B targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. Journal of Pathology, 2005, 206, 123-134.	2.1	126
15	Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood, 2003, 101, 4042-4046.	0.6	121
16	Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis showsÂunique features versus other indolent SM. Journal of Allergy and Clinical Immunology, 2014, 133, 520-528.e5.	1.5	118
17	Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling. Molecular Cancer, 2006, 5, 39.	7.9	108
18	Nodal Marginal Zone Lymphoma: A Heterogeneous Tumor. American Journal of Surgical Pathology, 2003, 27, 762-771.	2.1	106

#	Article	IF	Citations
19	Plk5, a Polo Box Domain-Only Protein with Specific Roles in Neuron Differentiation and Glioblastoma Suppression. Molecular and Cellular Biology, 2011, 31, 1225-1239.	1.1	99
20	P53 protein expression in lymphomas and reactive lymphoid tissue. Journal of Pathology, 1992, 166, 235-241.	2.1	97
21	Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets. Blood, 2012, 119, e9-e21.	0.6	91
22	miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood, 2011, 118, 1034-1040.	0.6	90
23	Evaluation of the WHO criteria for the classification of patients with mastocytosis. Modern Pathology, 2011, 24, 1157-1168.	2.9	89
24	Novel Genomic Imbalances in B-Cell Splenic Marginal Zone Lymphomas Revealed by Comparative Genomic Hybridization and Cytogenetics. American Journal of Pathology, 2001, 158, 1843-1850.	1.9	88
25	Expression Profiling of T-Cell Lymphomas Differentiates Peripheral and Lymphoblastic Lymphomas and Defines Survival Related Genes. Clinical Cancer Research, 2004, 10, 4971-4982.	3.2	88
26	Building an Outcome Predictor Model for Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2004, 164, 613-622.	1.9	87
27	Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget, 2017, 8, 68950-68963.	0.8	83
28	Risk stratification for <scp>S</scp>plenic <scp>M</scp>arginal <scp>Z</scp>one <scp>L</scp>ymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. British Journal of Haematology, 2012, 159, 164-171.	1.2	81
29	Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica, 2010, 95, 1122-1129.	1.7	79
30	Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas. Journal of Investigative Dermatology, 2017, 137, 197-206.	0.3	78
31	Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia. Haematologica, 2008, 93, 670-679.	1.7	77
32	<scp>CD</scp>30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology, 2013, 63, 780-787.	1.6	77
33	MYD88 (L265P) Somatic Mutation in Marginal Zone B-cell Lymphoma. American Journal of Surgical Pathology, 2015, 39, 644-651.	2.1	76
34	Worse Outcome in Primary Glioblastoma Multiforme With Concurrent Epidermal Growth Factor Receptor and p53 Alteration. American Journal of Clinical Pathology, 2009, 131, 257-263.	0.4	75
35	Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. Journal of Allergy and Clinical Immunology, 2016, 137, 168-178.e1.	1.5	72
36	Identification of survivalâ€related genes of the phosphatidylinositol 3â€²â€kinase signaling pathway in glioblastoma multiforme. Cancer, 2008, 112, 1575-1584.	2.0	67

#	Article	IF	Citations
37	Intrafollicular neoplasia/in situ follicular lymphoma: review of a series of 13 cases. Histopathology, 2010, 56, 658-662.	1.6	66
38	Complete Response After Imatinib Mesylate Therapy in a Patient With Well-Differentiated Systemic Mastocytosis. Journal of Clinical Oncology, 2012, 30, e126-e129.	0.8	59
39	Frequent involvement of chromosomes 1, 3, 7 and 8 in splenic marginal zone Bâ€cell lymphoma. British Journal of Haematology, 1997, 98, 446-449.	1.2	56
40	Aberrant Bcl6 Protein Expression in Mantle Cell Lymphoma. American Journal of Surgical Pathology, 2004, 28, 1051-1056.	2.1	55
41	Nodal and splenic marginal zone B cell lymphomas. Hematological Oncology, 2005, 23, 108-118.	0.8	54
42	Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro-Oncology, 2010, 12, 1278-1290.	0.6	54
43	The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature. Blood, 2014, 123, 2893-2894.	0.6	53
44	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. Blood, 2015, 125, 1922-1931.	0.6	53
45	Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations. Blood, 2017, 129, 1042-1045.	0.6	52
46	Splenic marginal zone lymphoma with increased number of blasts: An aggressive variant?. Human Pathology, 1999, 30, 1153-1160.	1.1	50
47	Large B-cell Lymphoma Presenting in the Spleen. American Journal of Surgical Pathology, 2003, 27, 895-902.	2.1	50
48	Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. Acta Neuropathologica, 2013, 126, 277-289.	3.9	49
49	Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood, 2022, 139, 732-747.	0.6	49
50	A Short Mutational Hot Spot in the First Intron of BCL-6 Is Associated with Increased BCL-6 Expression and with Longer Overall Survival in Large B-Cell Lymphomas. American Journal of Pathology, 2002, 160, 1371-1380.	1.9	47
51	A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood, 2010, 116, e12-e17.	0.6	47
52	Genetic Alterations Associated With Progression and Recurrence in Meningiomas. Journal of Neuropathology and Experimental Neurology, 2012, 71, 882-893.	0.9	47
53	Highâ€throughput sequencing analysis of the chromosome 7q32 deletion reveals <scp>IRF</scp>5 as a potential tumour suppressor in splenic marginalâ€zone lymphoma. British Journal of Haematology, 2012, 158, 712-726.	1.2	45
54	Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling. Modern Pathology, 2013, 26, 889-901.	2.9	45

#	Article	IF	Citations
55	Epigenetic downregulation of TET3 reduces genomeâ€wide 5hmC levels and promotes glioblastoma tumorigenesis. International Journal of Cancer, 2020, 146, 373-387.	2.3	45
56	Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood, 2002, 100, 1648-54.	0.6	45
57	Splenic Follicular Lymphoma. American Journal of Surgical Pathology, 2009, 33, 730-738.	2.1	41
58	Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients. Journal of Neuro-Oncology, 2015, 122, 441-450.	1.4	41
59	Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leukemia and Lymphoma, 2014, 55, 929-931.	0.6	40
60	Molecular Classification Defines 4 Prognostically Distinct Glioma Groups Irrespective of Diagnosis and Grade. Journal of Neuropathology and Experimental Neurology, 2015, 74, 241-249.	0.9	38
61	Monocytoid B Cells. American Journal of Surgical Pathology, 1994, 18, 1131-1139.	2.1	35
62	Variability in the Degree of Expression of Phosphorylated IÎºBÎ± in Chronic Lymphocytic Leukemia Cases With Nodal Involvement. Clinical Cancer Research, 2004, 10, 6796-6806.	3.2	35
63	Gene expression changes associated with erlotinib response in glioma cell lines. European Journal of Cancer, 2013, 49, 1641-1653.	1.3	35
64	Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. Annals of Allergy, Asthma and Immunology, 2013, 111, 425-426.	0.5	33
65	Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. Haematologica, 2013, 98, 57-64.	1.7	33
66	Splenic marginal zone lymphoma. Best Practice and Research in Clinical Haematology, 2017, 30, 56-64.	0.7	33
67	Glomerular C3d as a novel prognostic marker for renal vasculitis. Human Pathology, 2016, 56, 31-39.	1.1	31
68	Clinical and diagnostic relevance of NOTCH2 -and KLF2 -mutations in splenic marginal zone lymphoma. Haematologica, 2017, 102, e310-e312.	1.7	31
69	Molecular Study of Long-Term Survivors of Glioblastoma by Gene-Targeted Next-Generation Sequencing. Journal of Neuropathology and Experimental Neurology, 2018, 77, 710-716.	0.9	31
70	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. PLoS ONE, 2019, 14, e0212813.	1.1	31
71	Cutaneous Presentation of Follicular Lymphomas. Modern Pathology, 2001, 14, 913-919.	2.9	29
72	Cranial fasciitis of childhood with reactive periostitis. World Neurosurgery, 1990, 33, 146-149.	1.3	27

#	Article	IF	Citations
73	Unique Phenotypic Profile of Monocytoid B Cells. American Journal of Pathology, 2001, 158, 1363-1369.	1.9	27
74	Stimulation of ALK by the growth factor midkine renders glioma cells resistant to autophagy-mediated cell death. Autophagy, 2011, 7, 1071-1073.	4.3	27
75	NFÎºB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. Modern Pathology, 2014, 27, 1331-1337.	2.9	27
76	Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. Oncotarget, 2016, 7, 18036-18049.	0.8	26
77	Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma. Human Molecular Genetics, 2018, 27, 3046-3059.	1.4	26
78	C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas. Haematologica, 2016, 101, e336-e338.	1.7	25
79	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. Scientific Reports, 2021, 11, 1886.	1.6	25
80	Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers. Blood Advances, 2021, 5, 5588-5598.	2.5	24
81	BCR gene disruption in a pilomyxoid astrocytoma. Neuropathology, 2006, 26, 442-446.	0.7	23
82	Molecular Characterization of the Region 7q22.1 in Splenic Marginal Zone Lymphomas. PLoS ONE, 2011, 6, e24939.	1.1	23
83	Hepatitis C virus-related lymphoproliferative disorders encompass a broader clinical and morphological spectrum than previously recognized: a clinicopathological study. Modern Pathology, 2014, 27, 281-293.	2.9	22
84	Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation. Haematologica, 2015, 100, e200-e203.	1.7	21
85	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. British Journal of Haematology, 2010, 151, 435-439.	1.2	20
86	TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors. Neuro-Oncology Advances, 2020, 2, vdz059.	0.4	20
87	PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases. PLoS ONE, 2014, 9, e112148.	1.1	18
88	Development of a Real-Time Reverse Transcription Polymerase Chain Reaction Assay for c-myc Expression That Allows the Identification of a Subset of c-myc+ Diffuse Large B-Cell Lymphoma. Laboratory Investigation, 2003, 83, 143-152.	1.7	17
89	An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors. Clinical Cancer Research, 2016, 22, 2032-2040.	3.2	17
90	Mutations in the <scp>JAK</scp>/<scp>STAT</scp> pathway genes and activation of the pathway, a relevant finding in nodal Peripheral Tâ€cell lymphoma. British Journal of Haematology, 2018, 183, 497-501.	1.2	17

#	Article	IF	Citations
91	Marginal zone lymphoma. Seminars in Diagnostic Pathology, 2011, 28, 135-145.	1.0	15
92	Diagnosis and classification of mastocytosis in nonâ€specialized versus reference centres: a Spanish Network on Mastocytosis (<scp>REMA</scp>) study on 122 patients. British Journal of Haematology, 2016, 172, 56-63.	1.2	15
93	Secretory meningioma with KLF4 K409Q mutation in collision with glioma. , 2015, 34, 322-329.		14
94	Novel Genomic Alterations and Mechanisms Associated With Tumor Progression in Oligodendroglioma and Mixed Oligoastrocytoma. Journal of Neuropathology and Experimental Neurology, 2009, 68, 274-285.	0.9	13
95	Somatic hypermutation signature in B-cell low-grade lymphomas. Haematologica, 2008, 93, 1186-1194.	1.7	11
96	Erythema multiformeâ€like reaction resulting from vitamin K₁ oxide (phytomenadione) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.8	11
97	Spontaneously Ruptured Spleen Samples in Patients With Infectious Mononucleosis. American Journal of Clinical Pathology, 2018, 150, 310-317.	0.4	10
98	Improved demonstration of immunohistochemical prognostic markers for survival in follicular lymphoma cells. Modern Pathology, 2011, 24, 698-707.	2.9	9
99	Microarray-Based Comparative Genomic Hybridization (Array-CGH) as a Useful Tool for Identifying Genes Involved in Glioblastoma (GB). Methods in Molecular Biology, 2010, 653, 35-45.	0.4	8
100	Antineutrophil cytoplasmic antibody negative pauciâ€immune extracapillary glomerulonephritis. Nephrology, 2016, 21, 301-307.	0.7	7
101	Epigenetic Deregulation of the Histone Methyltransferase KMT5B Contributes to Malignant Transformation in Glioblastoma. Frontiers in Cell and Developmental Biology, 2021, 9, 671838.	1.8	6
102	Hairy cell leukemia, blastic type: description of spleen morphology and immunophenotype of a distinctive case. Leukemia and Lymphoma, 2011, 52, 1589-1592.	0.6	3
103	Intravascular large B-cell lymphoma in a kidney biopsy. Blood, 2016, 127, 2939-2939.	0.6	3
104	Comment on: â€œA Unique Clinicopathological Manifestation of Fungal Infection: A Case Series of Deep Dermatophytosis in Immunosuppressed Patientsâ€. American Journal of Clinical Dermatology, 2017, 18, 709-711.	3.3	3
105	Hairy cell leukemia variant. Journal of Hematopathology, 2011, 4, 13-16.	0.2	2
106	pâ€<scp>MAPK</scp>1 expression associated with poor prognosis in angioimmunoblastic Tâ€cell lymphoma patients. British Journal of Haematology, 2017, 176, 661-664.	1.2	2
107	Mastocytosis in the skin accompanied by pseudoâ€Kaposiâ€™s sarcoma. Journal of Dermatology, 2021, 48, 657-660.	0.6	1
108	Genomeâ€wide <scp>DNA</scp> profiling identifies clonal heterogeneity in marginal zone lymphomas. British Journal of Haematology, 2014, 164, 896-899.	1.2	0

#	Article	IF	Citations
109	Simultaneous occurrence of cutaneous mastocytosis and juvenile xanthogranuloma in a child: Random or true association?. Pediatric Dermatology, 2020, 37, 716-720.	0.5	0